Cargando…

High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis

Purpose: Central nervous system lymphoma (CNSL) is an aggressive non-Hodgkin's lymphoma (NHL) confined to the central nervous system (CNS). Orelabrutinib is an oral second-generation Bruton tyrosine kinase (BTK) inhibitor and a novel therapeutic strategy for CNSL. The purpose of this study was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yufeng, Li, Yajun, Zeng, Ruolan, He, Yizi, Liang, Liang, Ou, Lijia, Su, Chang, Zhou, Hui, Xiao, Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622989/ https://www.ncbi.nlm.nih.gov/pubmed/37928429 http://dx.doi.org/10.7150/jca.85756

Ejemplares similares

Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience
por: Suleman, Adam, et al.
Publicado: (2022)

Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma
por: Yu, Hui, et al.
Publicado: (2021)

P1160: METHOTREXATE IN COMBINATION WITH IBRUTINIB, THIOTEPA, RITUXIMAB (R-MTO) FOLLOWED BY AUTOLOGOUS STEM-CELL TRANSPLANT FOR PRIMARY CNS LYMPHOMA
por: Xing, LI-Jie, et al.
Publicado: (2023)

Global Research Trends on the Treatment of Diffuse Large B-Cell Lymphoma: A Bibliometric and Visualized Study
por: Duan, Qintong, et al.
Publicado: (2022)

Current status and future prospects of chimeric antigen receptor-T cell therapy in lymphoma research: A bibliometric analysis
por: Ou, Lijia, et al.
Publicado: (2023)

Orelabrutinib versus ibrutinib for patients with refractory/relapsed primary central nervous system lymphoma: An efficacy and safety analysis
por: Qiao, Lijiao, et al.
Publicado: (2023)

International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma
por: Khwaja, Jahanzaib, et al.
Publicado: (2022)

Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series
por: Yang, Chuanwei, et al.
Publicado: (2022)

Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma
por: Sun, Xuefei, et al.
Publicado: (2017)

Ferroptosis-Related Gene Signature: A New Method for Personalized Risk Assessment in Patients with Diffuse Large B-Cell Lymphoma
por: Chen, Huan, et al.
Publicado: (2021)

Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma
por: Zhao, Defeng, et al.
Publicado: (2014)

ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
por: Takezaki, Tatsuya, et al.
Publicado: (2020)

P1145: PRELIMINARY RESULTS OF PENPULIMAB COMBINED WITH RMA(RITUXIMAB, METHOTREXATE, AND CYTARABINE) FOR NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
por: Shen, Haorui, et al.
Publicado: (2023)

P1165: PRELIMINARY FINDINGS OF A PHASE Ⅱ STUDY OF CHEMO-FREE COMBINATION OF POMALIDOMIDE, ORELABRUTINIB, RITUXIMAB WITH SEQUENTIAL HIGH-DOSE METHOREXATE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA
por: Zhang, Yan, et al.
Publicado: (2023)

Whither thiotepa (for patients in the USA)?
por: Dardis, Christopher, et al.
Publicado: (2015)

P1150: A PROSPECTIVE PHASE II CLINICAL TRIAL USING CHIDAMIDE, TISLELIZUMAB, AND PEGASPARGASE IN COMBINATION WITH RADIOTHERAPY AS FIRST-LINE TREATMENT IN STAGES I/II OF EXTRANODAL NK/T-CELL LYMPHOMA
por: Zhou, Hui, et al.
Publicado: (2023)

High‐dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China
por: Chen, Cui, et al.
Publicado: (2019)

Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma
por: Delphine, Lebon, et al.
Publicado: (2023)

Thiotepa in the treatment of advanced breast cancer.
por: Lyons, A. R., et al.
Publicado: (1965)

P1223: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZRMA REGIMEN（ZANUBRUTINIB, RITUXIMAB, METHOTREXATE AND CYTARABINE)
por: Tang, Y.
Publicado: (2022)

PB2315: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZR OR ZRM REGIMEN (ZANUBRUTINIB, RITUXIMAB, METHOTREXATE)
por: Teng, Yue, et al.
Publicado: (2023)

Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient
por: Camus, Vincent, et al.
Publicado: (2018)

Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen
por: Young, Patricia A., et al.
Publicado: (2020)

The Role of Rituximab in Primary Central Nervous System Lymphoma
por: Bromberg, Jacoline E. C., et al.
Publicado: (2020)

The Combined Thiotepa and Testosterone Treatment of Cancer of the Breast
por: Brown, I. Scott, et al.
Publicado: (1964)

Identification and Validation of a Prognostic Gene Signature for Diffuse Large B-Cell Lymphoma Based on Tumor Microenvironment-Related Genes
por: Pan, Tao, et al.
Publicado: (2021)

Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
por: Song, Yuqin, et al.
Publicado: (2023)

Survival Analysis of Hepatosplenic T Cell Lymphoma: A Population-Based Study Using SEER
por: Li, Yajun, et al.
Publicado: (2021)

CD 5+ Peripheral B Cell Lymphoma With Transformation to CD 5+ Diffuse Large B Cell Lymphoma in the CNS: A Case Report Treated With Rituximab, High Dose Methotrexate, Cytarabine, and Intrathecal Methotrexate
por: Uczkowski, Dariusz, et al.
Publicado: (2022)

Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma
por: Hu, Xin, et al.
Publicado: (2017)

Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS
por: Nagle, Sarah J, et al.
Publicado: (2017)

The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma
por: Van Dijck, Ruben, et al.
Publicado: (2021)

ML-14 LOW INVASIVE APPROACH FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA TREATMENT INVOLVING RITUXIMAB–METHOTREXATE + PROCARBAZINE + VINCRISTINE AND TRIPLE INTRATHECAL INJECTION
por: Ogawa, Takahiro, et al.
Publicado: (2019)

Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma
por: Dührsen, Ulrich, et al.
Publicado: (2021)

Successful Treatment of Primary CNS Extranodal NK/T-Cell Lymphoma with Surgery and Chemotherapy Combined with Sintilimab: A Case Report and Literature Review
por: Qin, Liping, et al.
Publicado: (2022)

Development of a UPLC-MS/MS method for the determination of orelabrutinib in rat plasma and its application in pharmacokinetics
por: Liu, Ya-nan, et al.
Publicado: (2022)

High-dose thiotepa-related neurotoxicity and the role of tramadol in children
por: Maritaz, Christophe, et al.
Publicado: (2018)

Rituximab/methotrexate: Lack of efficacy: case report
Publicado: (2022)

Methotrexate/rituximab/tozinameran interaction: Brain death secondary to the COVID-19 pneumonia: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5hvueqoltd8iia18pjdlkcc1bg